<DOC>
	<DOCNO>NCT01442649</DOCNO>
	<brief_summary>The main objective evaluate progression-free survival ( PFS ) 4 month . The secondary objective evaluate objective response rate ( OR ) ( = complete response ( CR ) partial response ( PR ) ) accord RECIST v1.1 criterion , progression-free survival ( PFS ) , overall survival ( OS ) , overall survival date first-line chemotherapy use metastatic disease , treatment tolerance ( NCI CTC AE V4 criterion , except peripheral neurological toxicity ( Lévi Scale ) ) , quality life accord EORTC QLQ-C30 criterion . The objective biological study evaluate potentially predictive anti-EGFR anti-VEGF response factor CEC rate predictive biomarkers efficacy bevacizumab associate chemotherapy mCRC treatment .</brief_summary>
	<brief_title>Efficacy Chemotherapy , Associated Either Cetuximab Bevacizumab , KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Histologically cytologically proven adenocarcinoma colon express nonmutated ( wildtype ) KRAS . Progressive metastatic disease firstline treatment chemotherapy alone : base 5FU ( iv per o ) irinotecan oxaliplatin associate bevacizumab . Prior adjuvant chemotherapy ( primary tumor ) fluoropyrimidine oxaliplatin allow time interval end chemotherapy begin firstline metastatic treatment ≥ 6 month . Measurable disease ( least one measurable metastatic lesion ) accord RECIST V1.1 criterion ( lesion locate previous field radiation ) . Previous radiotherapy authorize discontinue ≥ 15 day prior randomization measurable metastatic lesion outside radiation area . Sites disease evaluate within 28 day prior randomization thoracicabdominalpelvic CT scan ( abdominalpelvic MRI plus Chest Xray ) Age ≥18 year Patient ECOG 0 1 Life Expectancy ≥ 3 month Hematologic function ( polynuclear neutrophile ≥ 1.5.109/L ; platelet ≥ 100.109/L ; hemoglobin ≥ 9 g/dL Hepatic transaminases ≤ 2.5 time upper limit normal ( ULN ) ( ≤ 5 ULN case hepatic metastasis ) , alkaline phosphatase ≤ 2.5 ULN ( ≤ 5 ULN case hepatic metastasis ) , total bilirubinemia ≤ 1.5 ULN Renal function ( creatinemia ≤1.5 ULN ; creatine clearance ≥ 50 mL/mn ( Cockcroft Gault ) ; urine test strip &lt; 2+ . If proteinuria ≥ +2 inclusion , serum urea test must redo show proteinuria ≤ 1 g/L within 24 h ) Completion EORTC QLQC30 quality life form Negative pregnancy test woman childbearing age Information give patient sign informed consent Public Health insurance coverage Known meningeal brain metastasis Pretreatment antiEGFR Specific contraindication know hypersensitivity one treatment product Patient know allergy hypersensitivity monoclonal antibody ( bevacizumab , cetuximab Clinically significant affection coronary myocardial infarction within 6 month prior inclusion . Peripheral neuropathy grade &gt; 1 ( CTCAE scale version 4.0 ) . Known depletion dihydropyrimidine dehydrogenase ( DPD ) . Acute intestinal obstruction subobstruction , history inflammatory intestinal disease extend resection small intestine . Presence colic prosthesis . Uncontrolled Arterial hypertension ( systolic pressure &gt; 150 mmHg and/or diastolic pressure &gt; 100 mmHg without antihypertensive medication . Patients high hypertension eligible antihypertensive medication lower arterial pressure level acceptability specify inclusion criterion . History hypertensive crisis hypertensive encephalopathy Other concomitant malignancy history cancer ( except carcinoma situ cervix , non melanoma skin cancer , curative intent treatment , consider complete remission least 5 year randomization . Any treatment include experimental drug , participation another clinical trial within 28 day precede inclusion . Persons deprive liberty guardianship . Psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Second-line treatment</keyword>
	<keyword>Progressive disease first-line treatment bevacizumab</keyword>
	<keyword>Non-mutated ( wild-type ) KRAS .</keyword>
</DOC>